Home / ACHFF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ACHFF make money? Does ACHFF have pricing power? What's the Earnings Whisper? Will ACHFF profit more as the business scales? What is ACHFF's management track record? Is ACHFF's current price justified?

Arch Biopartners Inc.

$0.65 -$0.25 (-27.61%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$0.62

Day Range

$0.65$0.68

Year Range

$0.29$1.21

Market Cap

44.16M

AVG Volume

24.57K

Trailing/Forward PE

-21.65/-

PEG ratio

0.29

Dividend Yield

Next Earnings Date

2027-02-02

Primary Exchange

Other OTC

Revenue (CAD)

ACHFF Revenue (CAD) by quarter
Period	Revenue (CAD)
26 Q3	0
26 Q2	0
26 Q1	0
25 Q4	0
25 Q3	158.08K
25 Q2	0
25 Q1	117.86K
24 Q4	-361K
24 Q3	855
24 Q2	2.18M

Net Income (CAD)

ACHFF Net Income (CAD) by quarter
Period	Net Income (CAD)
26 Q3	-459.97K
26 Q2	-522.35K
26 Q1	-1.56M
25 Q4	-269.76K
25 Q3	-242.33K
25 Q2	-624K
25 Q1	-416K
24 Q4	-1.1M
24 Q3	-885K
24 Q2	-1.15M

Operating Income (CAD)

ACHFF Operating Income (CAD) by quarter
Period	Operating Income (CAD)
26 Q3	-423.28K
26 Q2	-460.61K
26 Q1	-1.48M
25 Q4	-279.2K
25 Q3	-275.33K
25 Q2	-587.97K
25 Q1	-357K
24 Q4	-1.15M
24 Q3	-863K
24 Q2	-1.14M

EBITDA (CAD)

ACHFF EBITDA (CAD) by quarter
Period	EBITDA (CAD)
26 Q3	-423.28K
26 Q2	-460.61K
26 Q1	-1.48M
25 Q4	-207.47K
25 Q3	-183.46K
25 Q2	-50.67K
25 Q1	-92.61K
24 Q4	-987.23K
24 Q3	-789.28K
24 Q2	-1.06M

Cash Flows (CAD)

ACHFF Cash Flows (CAD) by quarter
Period	Cash Flows (CAD)
26 Q3	-504.38K
26 Q2	-89.34K
26 Q1	-849.25K
25 Q4	-257.9K
25 Q3	113.72K
25 Q2	-574.64K
25 Q1	-903.05K
24 Q4	-469.84K
24 Q3	-864.11K
24 Q2	-465.38K

EPS (CAD)

ACHFF EPS (CAD) by quarter
Period	EPS (CAD)
26 Q3	-0.01
26 Q2	-0.01
26 Q1	-0.02
25 Q4	-0
25 Q3	-0
25 Q2	-0.01
25 Q1	-0.01
24 Q4	-0.02
24 Q3	-0.01
24 Q2	-0.02

Expenses (CAD)

ACHFF Expenses (CAD) by quarter
Period	Expenses (CAD)
26 Q3	374.05K
26 Q2	355.44K
26 Q1	1.4M
25 Q4	16.33K
25 Q3	317.18K
25 Q2	470.19K
25 Q1	333.78K
24 Q4	667.48K
24 Q3	708.84K
24 Q2	3.13M

Cash & Debt (CAD)

ACHFF Cash & Debt (CAD) by quarter
Period	Cash & Debt (CAD)
26 Q3	2.92K
26 Q2	437.89K
26 Q1	4.16K
25 Q4	2.1K
25 Q3	167.46K
25 Q2	10.03K
25 Q1	54.85K
24 Q4	2.97K
24 Q3	43.95K
24 Q2	6.56K

Debt ratios

ACHFF Debt ratios by quarter
Period	Debt ratios
26 Q3	-1.06
26 Q2	-0.99
26 Q1	-1.37
25 Q4	-5.32
25 Q3	-1.73
25 Q2	-1.24
25 Q1	-0.95
24 Q4	-0.78
24 Q3	-2.42
24 Q2	-3.85

Margins

ACHFF Margins by quarter
Period	Margins
25 Q3	27.41%
25 Q1	13.29%
24 Q4	207.76%
24 Q3	-55321.64%
24 Q2	-25.69%
24 Q1	43.07%
23 Q4	266.61%
23 Q3	-169.29%
23 Q2	-24.97%
23 Q1	-7.54%

Return on Capital

ACHFF Return on Capital by quarter
Period	Return on Capital
26 Q3	11.54%
26 Q2	14.3%
26 Q1	43.33%
25 Q4	6.95%
25 Q3	6.63%
25 Q2	16.56%
25 Q1	9.76%
24 Q4	25.39%
24 Q3	13.5%
24 Q2	17.86%

Shares Outstanding

ACHFF Shares Outstanding by quarter
Period	Shares Outstanding
26 Q3	67.93M
26 Q2	66.94M
26 Q1	66.11M
25 Q4	66.11M
25 Q3	66.11M
25 Q2	64.94M
25 Q1	64.94M
24 Q4	60.77M
24 Q3	62.76M
24 Q2	62.76M

Book Value Per Share (CAD)

ACHFF Book Value Per Share (CAD) by quarter
Period	Book Value Per Share (CAD)
26 Q3	-0.06
26 Q2	-0.05
26 Q1	-0.05
25 Q4	-0.06
25 Q3	-0.06
25 Q2	-0.06
25 Q1	-0.07
24 Q4	-0.07
24 Q3	-0.1
24 Q2	-0.1

Total Assets (CAD)

ACHFF Total Assets (CAD) by quarter
Period	Total Assets (CAD)
26 Q3	57.24K
26 Q2	464.36K
26 Q1	25.01K
25 Q4	104.53K
25 Q3	266.46K
25 Q2	549.64K
25 Q1	533.53K
24 Q4	935.62K
24 Q3	1.54M
24 Q2	1.79M

PE Ratio

ACHFF PE Ratio by quarter
Period	PE Ratio
Sep 22	212.84
Sep 22	226.6
Sep 22	227.98
Sep 22	228.68
Aug 22	243.19
Aug 22	239.42
Aug 22	248.08
Aug 22	244.81
Jul 22	250.3
Jul 22	248.07
Jul 22	250.22
Jul 22	259.51
Jul 22	213.68
Jun 22	550.41
Jun 22	576.85
Jun 22	598.81
Jun 22	591.46
May 22	608.33
May 22	627.35
May 22	716.79
May 22	780.21
Apr 22	787.38
Apr 22	802.53
Apr 22	814.05
Apr 22	817.49
Apr 22	833.43

Free Cash Flow Yield

ACHFF Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-1.79%
Sep 26	-1.58%
Aug 26	-1.55%
Aug 26	-1.48%
Aug 26	-1.41%
Aug 26	-1.58%
Jul 26	-2.01%
Jul 26	-1.9%
Jul 26	-1.91%
Jul 26	-1.91%
Jul 26	-1.88%
Jun 26	-2.6%
Jun 26	-3.49%
Jun 26	-4.81%
Jun 26	-4.84%
May 26	-5.42%
May 26	-5.37%
May 26	-5.57%
May 26	-5.41%
May 26	-5.42%
Apr 26	-5.05%
Apr 26	-5.19%
Apr 26	-4.3%
Apr 26	-4.21%
Mar 26	-4.53%
Mar 26	-4.43%
Mar 26	-3.59%
Mar 26	-3.14%
Feb 26	-3.09%
Feb 26	-2.7%
Feb 26	-2.64%
Feb 26	-3.06%
Jan 26	-2.36%
Jan 26	-1.97%
Jan 26	-1.78%
Jan 26	-1.85%
Jan 26	-1.99%
Dec 25	-2.25%
Dec 25	-2.27%
Dec 25	-2.2%
Dec 25	-2.17%
Nov 25	-2.67%
Nov 25	-2.7%
Nov 25	-2.65%
Nov 25	-2.65%
Oct 25	-2.8%
Oct 25	-2.85%
Oct 25	-2.89%
Oct 25	-2.52%
Oct 25	-2.3%
Sep 25	-3.11%
Sep 25	-2.62%
Sep 25	-2.63%
Sep 25	-2.72%
Aug 25	-2.6%
Aug 25	-2.61%
Aug 25	-2.59%
Aug 25	-2.54%
Aug 25	-2.51%
Jul 25	-2.66%
Jul 25	-2.5%
Jul 25	-2.51%
Jul 25	-2.45%
Jun 25	-2.24%
Jun 25	-2.41%
Jun 25	-2.24%
Jun 25	-2.25%
May 25	-2.35%
May 25	-2.39%
May 25	-2.44%
May 25	-2.41%
May 25	-2.39%
Apr 25	-2.38%
Apr 25	-2.37%
Apr 25	-2.22%
Apr 25	-2.46%
Mar 25	-2.25%
Mar 25	-2.1%
Mar 25	-2.07%
Mar 25	-2.2%
Feb 25	-2.12%
Feb 25	-2.01%
Feb 25	-2.06%
Feb 25	-2.05%
Jan 25	-2.11%
Jan 25	-2.01%
Jan 25	-2.04%
Jan 25	-2%
Jan 25	-1.94%
Dec 24	-2.38%
Dec 24	-2.5%
Dec 24	-2.32%
Dec 24	-2.23%
Nov 24	-2.22%
Nov 24	-2.26%
Nov 24	-2.16%
Nov 24	-2.16%
Nov 24	-2.26%
Oct 24	-2.16%
Oct 24	-2.09%

Price to Sales

ACHFF Price to Sales by quarter
Period	Price to Sales
Sep 26	381.76
Sep 26	433.42
Aug 26	441.49
Aug 26	463.86
Aug 26	484.49
Aug 26	432.84
Jul 26	339.98
Jul 26	360.96
Jul 26	358.18
Jul 26	358.56
Jul 26	365.09
Jun 26	381.08
Jun 26	284.53
Jun 26	206.25
Jun 26	204.93
May 26	182.85
May 26	184.87
May 26	178.18
May 26	183.33
May 26	182.93
Apr 26	196.61
Apr 26	191.02
Apr 26	230.73
Apr 26	235.83
Mar 26	129.77
Mar 26	132.75
Mar 26	163.52
Mar 26	187.26
Feb 26	190.18
Feb 26	217.94
Feb 26	222.91
Feb 26	191.9
Jan 26	249.53
Jan 26	298.98
Jan 26	330.11
Jan 26	318.24
Jan 26	295.27
Dec 25	-956.25
Dec 25	-950.43
Dec 25	-980.93
Dec 25	-994.2
Nov 25	-808.65
Nov 25	-799.9
Nov 25	-812.66
Nov 25	-812.13
Oct 25	-770.56
Oct 25	-755.74
Oct 25	-746.25
Oct 25	-853.9
Oct 25	-939.39
Sep 25	-373.59
Sep 25	-442.95
Sep 25	-441.56
Sep 25	-426.1
Aug 25	-445.55
Aug 25	-444.52
Aug 25	-448.02
Aug 25	-457.14
Aug 25	-461.93
Jul 25	-436.89
Jul 25	-463.3
Jul 25	-462.16
Jul 25	-473.26
Jun 25	62.21
Jun 25	57.87
Jun 25	62.21
Jun 25	61.8
May 25	59.26
May 25	58.31
May 25	56.98
May 25	57.77
May 25	58.2
Apr 25	58.35
Apr 25	58.75
Apr 25	62.59
Apr 25	56.62
Mar 25	49.18
Mar 25	52.6
Mar 25	53.49
Mar 25	50.18
Feb 25	52.17
Feb 25	54.95
Feb 25	53.6
Feb 25	54
Jan 25	52.4
Jan 25	55.03
Jan 25	54.31
Jan 25	55.32
Jan 25	57.08
Dec 24	82.98
Dec 24	78.84
Dec 24	85.16
Dec 24	88.54
Nov 24	88.87
Nov 24	87.42
Nov 24	91.32
Nov 24	91.41
Nov 24	87.25
Oct 24	91.31
Oct 24	94.47

EV/EBITDA

ACHFF EV/EBITDA by quarter
Period	EV/EBITDA
Mar 24	319.5
Mar 24	349.3
Mar 24	310.04
Mar 24	250.79
Mar 24	218.22
Feb 24	219.35
Feb 24	203.97
Feb 24	207.36
Feb 24	201.85
Jan 24	225.84
Jan 24	218.03
Jan 24	215.87
Jan 24	211.42
Dec 23	215.24
Dec 23	1249.84
Dec 23	1226.91
Dec 23	1211.14
Dec 23	1259.22
Nov 23	955.52
Nov 23	968.58
Nov 23	882.71
Nov 23	864.36
Oct 23	910.35
Oct 23	940.37
Oct 23	964.57
Oct 23	936.6
Sep 23	953.84
Dec 22	244.21
Dec 22	257.47
Dec 22	258.84
Dec 22	259.55
Nov 22	258.93
Nov 22	267.33
Nov 22	279.58
Nov 22	286.93
Oct 22	288.33
Oct 22	289.17
Oct 22	267.42
Oct 22	264.5
Sep 22	269.92
Sep 22	112.22
Sep 22	119.33
Sep 22	120.04
Sep 22	120.4
Aug 22	127.91
Aug 22	125.96
Aug 22	130.44
Aug 22	128.75
Jul 22	131.59
Jul 22	130.44
Jul 22	131.55
Jul 22	136.35
Jul 22	112.65
Jun 22	105.7
Jun 22	110.67
Jun 22	114.79
Jun 22	113.41
May 22	116.58
May 22	120.16
May 22	136.97
May 22	148.9
Apr 22	150.24
Apr 22	153.09
Apr 22	155.26
Apr 22	155.9
Apr 22	158.9
Mar 22	148.03
Mar 22	138.17
Mar 22	128.72
Mar 22	125.63
Feb 22	125.86
Feb 22	137.8
Feb 22	141.96
Feb 22	139.9
Jan 22	126.5
Jan 22	136.34
Jan 22	138.09
Jan 22	140.5
Dec 21	133.35
Dec 21	264.76
Dec 21	275.62
Dec 21	291.76
Dec 21	338.82
Nov 21	323.53
Nov 21	289.83
Nov 21	254.65
Nov 21	226.22
Oct 21	201.08
Oct 21	184.73
Oct 21	171.86
Oct 21	149.11
Oct 21	126.15

Price/Operating Cashflow

ACHFF Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Dec 23	52.01
Dec 23	51.02
Dec 23	50.34
Dec 23	52.42
Nov 23	39.28
Nov 23	39.85
Nov 23	36.13
Nov 23	35.34
Oct 23	37.33
Oct 23	38.63
Oct 23	39.67
Oct 23	38.46
Sep 23	39.21
Mar 23	282.2
Mar 23	272.05
Mar 23	303.67
Mar 23	333.06
Feb 23	275.93
Feb 23	322.23
Feb 23	346.89
Feb 23	348.41
Jan 23	350.8
Jan 23	372.1
Jan 23	393.46
Jan 23	356.49
Dec 22	366.15

No video analysis for this stock yet. Request one from our team.

News: ACHFF

globenewswire.com · 31 Aug 2026

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide

TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company's ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”).

globenewswire.com · 17 Jul 2026

Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program

TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company's pre-IND IL-32 chronic kidney disease (“CKD”) program.

globenewswire.com · 8 Jul 2026

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair.